198 related articles for article (PubMed ID: 28944080)
1. Predicting ligand-dependent tumors from multi-dimensional signaling features.
Hass H; Masson K; Wohlgemuth S; Paragas V; Allen JE; Sevecka M; Pace E; Timmer J; Stelling J; MacBeath G; Schoeberl B; Raue A
NPJ Syst Biol Appl; 2017; 3():27. PubMed ID: 28944080
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L; Strommen K; Dao-Pick T; Parry G; Goodman L; Winslow J
Breast Cancer Res; 2011 Apr; 13(2):R44. PubMed ID: 21496232
[TBL] [Abstract][Full Text] [Related]
3. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
4. A view on EGFR-targeted therapies from the oncogene-addiction perspective.
Perez R; Crombet T; de Leon J; Moreno E
Front Pharmacol; 2013; 4():53. PubMed ID: 23637683
[TBL] [Abstract][Full Text] [Related]
5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.
Vigna E; Chiriaco C; Cignetto S; Fontani L; Basilico C; Petronzelli F; Comoglio PM
Mol Oncol; 2015 Nov; 9(9):1760-72. PubMed ID: 26119717
[TBL] [Abstract][Full Text] [Related]
7. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
McDermott U; Ames RY; Iafrate AJ; Maheswaran S; Stubbs H; Greninger P; McCutcheon K; Milano R; Tam A; Lee DY; Lucien L; Brannigan BW; Ulkus LE; Ma XJ; Erlander MG; Haber DA; Sharma SV; Settleman J
Cancer Res; 2009 May; 69(9):3937-46. PubMed ID: 19366796
[TBL] [Abstract][Full Text] [Related]
8. An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies.
Orlando E; Medo M; Bensimon A; Quintin A; Riedo R; Roth SM; Riether C; Marti TM; Aebersold DM; Medová M; Aebersold R; Zimmer Y
Cell Mol Life Sci; 2022 Dec; 80(1):6. PubMed ID: 36494469
[TBL] [Abstract][Full Text] [Related]
9. Downregulating Neuropilin-2 Triggers a Novel Mechanism Enabling EGFR-Dependent Resistance to Oncogene-Targeted Therapies.
Rizzolio S; Battistini C; Cagnoni G; Apicella M; Vella V; Giordano S; Tamagnone L
Cancer Res; 2018 Feb; 78(4):1058-1068. PubMed ID: 29229599
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
11. Analysis of growth factor signaling in genetically diverse breast cancer lines.
Niepel M; Hafner M; Pace EA; Chung M; Chai DH; Zhou L; Muhlich JL; Schoeberl B; Sorger PK
BMC Biol; 2014 Mar; 12():20. PubMed ID: 24655548
[TBL] [Abstract][Full Text] [Related]
12. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.
Lo WW; Wunder JS; Dickson BC; Campbell V; McGovern K; Alman BA; Andrulis IL
Cancer; 2014 Feb; 120(4):537-47. PubMed ID: 24151134
[TBL] [Abstract][Full Text] [Related]
13. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
15. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
16. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells.
Yanochko GM; Eckhart W
Breast Cancer Res; 2006; 8(2):R18. PubMed ID: 16584539
[TBL] [Abstract][Full Text] [Related]
17. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
18. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
Bellovin DI; Das B; Felsher DW
Adv Exp Med Biol; 2013; 734():91-107. PubMed ID: 23143977
[TBL] [Abstract][Full Text] [Related]
19. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Pal S; Shankar BS; Sainis KB
Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
[TBL] [Abstract][Full Text] [Related]
20. Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.
Konda JD; Olivero M; Musiani D; Lamba S; Di Renzo MF
Mol Oncol; 2017 Jun; 11(6):599-611. PubMed ID: 28182330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]